Engflag

Percin

Quick links to important sections

Percin

Percin_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Percin

Property Description
Active ingredient Prulifloxacin
Form Oral Tablet
Pharmacological class Synthetic Fluoroquinolone Antibiotic
Common use Resolution of systemic bacterial infections
Origin Synthetic organic compound; Prodrug

What Type of Medicine is Percin? (Identity and Classification)

Percin is classified as a synthetic fluoroquinolone antibiotic, functioning as a powerful anti-infective agent for systemic use. This single-ingredient product, whose core component is Prulifloxacin, is identified as an orally administered fluoroquinolone. This classification confirms the drug's specialized nature as a potent, synthetic antibacterial agent, typically reserved for use in adults.

As a member of the fluoroquinolone class, Percin is distinguished by its broad-spectrum activity and definitive bactericidal action, which effectively eliminates a wide range of microbial pathogens. This compound represents a modern development in the class, engineered to address established infections when a definitive, broad-acting agent is necessary.

Composition and Prodrug Nature (Chemical Makeup and Form)

The sole active ingredient in Percin is Prulifloxacin, which is administered via the oral route as a Tablet. Prulifloxacin is distinct because it functions as a prodrug, meaning the initial substance is biologically inactive.

This prodrug is metabolized by the body into the active substance Ulifloxacin. This mechanism of being activated inside the body is a specific design feature, ensuring the potent antibacterial agent is delivered to the systemic circulation effectively after conversion. The final tablet composition is a solid form comprising the active substance and the necessary, inert pharmaceutical excipients.

General Purpose and Action (High-Level Therapeutic Scope)

The general purpose of Percin is the definitive resolution of infectious diseases, achieved by applying a reliable bactericidal action against the pathogen. Its therapeutic goal involves inhibiting essential life functions of the bacterial cell.

The drug's broad-spectrum activity ensures it targets a wide range of harmful microbes, encompassing both Gram-negative bacteria and Gram-positive bacteria. Consequently, this potent anti-infective agent is generally used to relieve symptoms associated with systemic bacterial infections, such as complicated urinary tract infections or acute lower respiratory tract infections, where swift pathogen elimination is critical.

What side effects are possible with Percin?

Possible side effects and safety information

The safety profile of Percin, as a systemic fluoroquinolone antibiotic, is defined by classifications of adverse reactions across several physiological systems and specific regulatory warnings regarding serious effects. The information presented here is strictly aligned with regulatory documents, such as those published by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Adverse Reaction Classification

Side effects documented in regulatory labeling are often categorized by frequency and the body system affected:

  • Common Reactions: Adverse reactions officially classified as common include reactions in the Gastrointestinal system (such as nausea, diarrhea, and gastric pain) and the Dermatological system (skin rash).
  • System-Organ Classes: Documented effects also involve the Nervous System (headache, dizziness) and the Musculoskeletal and Connective Tissue Disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the potential for serious adverse reactions associated with the fluoroquinolone class. These serious effects can be disabling and potentially irreversible:

  • Musculoskeletal and Neurological Risks: Documented serious adverse reactions include tendinitis and tendon rupture, peripheral neuropathy (nerve damage), and severe central nervous system effects like psychosis and suicidal ideation.
  • Other Serious Effects: The safety profile also includes risks of Severe hypoglycemia and the Exacerbation of myasthenia gravis.

Population-Specific and Time-Related Safety

Risk assessment is stratified for specific populations. Regulatory documents highlight an increased risk of tendon damage and blood glucose issues in older patients and those with renal impairment or who have had solid organ transplants. These serious adverse effects may manifest as early as within 48 hours of treatment initiation or up to several months after discontinuation.

Overdose and Emergency Response

Official guidance dictates that acute overdosage with Percin requires immediate medical attention. Regulators note that a unique symptom profile is not specifically documented for Prulifloxacin overexposure; instead, the focus is on managing the systemic risk of life-threatening class effects associated with systemic fluoroquinolones. Severe outcomes involve the Central Nervous System (CNS) with risk of convulsions, confusion, or psychosis; the Cardiovascular System (risk of QT interval prolongation and Torsade de Pointes); and the Metabolic System (risk of severe hypoglycemia that can lead to coma).

The mandatory procedural instruction requires initiating stomach emptying through methods such as gastric lavage or inducing vomiting. The patient must be carefully observed and provided with symptomatic and general supportive treatment because no specific antidote is formally known or available to reverse the drug's effects. Monitoring is required to manage the potential for these severe class effects.

Regulatory information further notes increased risks for serious adverse events following overexposure in certain populations, specifically older patients and individuals with diabetes or renal impairment. Management is strictly supportive and procedural, as defined by regulatory documents.

Therapeutic Uses of Percin

What Percin Treats: Main Uses and Benefits

Percin (Prulifloxacin) is a broad-spectrum anti-infective agent generally used for managing systemic bacterial illnesses in adult patients. Its primary therapeutic benefit is that it aims to support the clearance of causative pathogens, which may assist with managing acute, disruptive symptoms.

Targeting Key Symptom Domains

Percin is applied in clinical settings that may involve acute or fluctuating symptom patterns across three main domains: genitourinary tract infections (like complicated UTIs and prostatitis), lower respiratory tract infections (such as acute exacerbations of chronic bronchitis), and certain gastrointestinal or skin infections. This medication plays a role in managing symptoms that may become intense or disruptive, including the pronounced discomfort of painful urination (dysuria), sudden breathing difficulties related to chest infections, and systemic distress from enteric pathogens.

It is relevant when supportive symptom management is appropriate and contributes to improved day-to-day comfort.

“This medication is commonly used across conditions presenting with acute episodes and is helpful in situations where multiple symptoms occur together.”

Quick Fact: Relief for Acute Discomfort Percin is generally used for managing conditions involving inflammatory or irritative processes that present with symptoms, and provides support that may help ease the overall symptom burden during periods of heightened discomfort.

Regulatory References

  1. EMA Fluoroquinolone referral information

Eligibility and Restrictions for Use

This information is based on the official regulatory documentation for the active substance prulifloxacin, a fluoroquinolone class antibiotic.

Eligibility Restrictions

Percin is strictly contraindicated in the following populations:

  • Individuals with a known hypersensitivity or allergy to prulifloxacin, any other quinolone antibacterial agent, or any of the product's excipients.
  • Children and adolescents under 18 years of age due to safety concerns and incomplete skeletal development.
  • Patients with a history of tendon disorders related to the administration of any quinolone or fluoroquinolone.
  • Individuals who are pregnant or breastfeeding.

Use is specifically restricted or requires special consideration in the following groups:

  • Patients with a known history of Myasthenia Gravis (a condition of muscle weakness), as the drug may exacerbate symptoms.
  • Patients with epilepsy or other conditions that predispose to seizures, as the drug may lower the seizure threshold.
  • Older patients (typically over 60 years) have an increased risk of tendon damage, as do patients with renal impairment (kidney issues) or those who have had an organ transplant.
  • Use should be avoided in patients who have experienced serious side effects when using any quinolone or fluoroquinolone product in the past. Treatment for these individuals should only be initiated if there are no alternative therapeutic options.

What should I know about interactions with other medicines?

Percin (prulifloxacin, a fluoroquinolone antibiotic) can interact with several other medications and certain products, which may affect how Percin works or increase the risk of side effects. It is critical to inform your healthcare provider about all medicines, over-the-counter drugs, and supplements you are currently taking.

Potential Drug-Drug Interactions

Percin should be used with caution when taken with certain drug classes:

  • Antacids and Supplements: Medications or supplements containing aluminum, magnesium, calcium, iron, or zinc may bind to Percin in the digestive tract, significantly reducing its absorption and effectiveness. This includes antacids, certain proton pump inhibitors, and mineral supplements. Administration should be separated by at least two hours.
  • Anticoagulants (Blood Thinners): When Percin is taken concurrently with warfarin, the effect of the anticoagulant may be enhanced, increasing the risk of bleeding. Close monitoring of blood clotting time (INR) is necessary.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Combining Percin with certain NSAIDs, such as ibuprofen or naproxen, may increase the risk of central nervous system stimulation, potentially leading to convulsions (seizures).

Drug-Food/Product Interactions

  • Dairy Products: Avoid consuming milk, cheese, and other dairy products within two hours of taking Percin, as they can interfere with drug absorption, reducing its therapeutic effect. The tablets should be taken with water on an empty stomach.
  • Alcohol: Consumption of alcohol is generally not recommended during Percin therapy, as it may increase the risk or severity of certain side effects.

Mechanism of Action

Direct Inhibition of Bacterial DNA Topoisomerases

The active molecule Ulifloxacin targets two bacterial enzymes central to DNA function: DNA Gyrase and Topoisomerase IV. These enzymes are crucial for unwinding and separating DNA strands during cell replication and repair. Ulifloxacin acts as an inhibitor by stabilizing the intermediate DNA cleavage complex, which halts the re-ligation step and facilitates the functional toxicity of the enzyme-DNA structure.

The Cytotoxic Bactericidal Cascade

By trapping the DNA topoisomerases on the DNA, the drug induces persistent double-strand DNA breaks. The resulting damage to the bacterial genome triggers the induced process of bacterial cell death. This specific cascade leads to the bactericidal action that terminates the viability of the microbial population.

Mechanistic Constraints by Resistance

This domain addresses the biological factors that constrain the drug's mechanism of action. The mechanism is limited when bacteria acquire genetic changes that reduce Ulifloxacin's affinity for its targets. The two main pathways involve point mutations in the target genes (gyrA and parC) and the over-expression of efflux pumps that actively expel the drug from the bacterial cell. These mechanisms reduce the concentration of the active molecule at the site of action, constraining the drug’s ability to induce DNA damage.

Dosage and Administration Information

How to Use Percin — Standard Administration Guidelines

Percin is administered orally and must be used strictly according to the dose and duration prescribed by your healthcare provider. It is essential to complete the full course of treatment as directed.

Administration Component Instruction
Route & Form Oral tablet. Swallow the tablet whole. Do not split, crush, or chew.
Dosing Schedule Take the prescribed dose once daily (QD). The treatment duration must be completed.
Timing with Food Must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal). Should not be taken with dairy products (e.g., milk, yogurt) or calcium-fortified beverages.
Missed Dose If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose. Do not take two doses at once.
Pediatric Use Safety and efficacy in the pediatric population are not established, and its use is generally not recommended in children and adolescents.

Established guidelines define the required steps for using Percin, specifying the tablet must be swallowed whole daily and must be taken on an empty stomach to ensure the drug's proper absorption. These directions are necessary for the correct use of the medicine, emphasizing that the entire treatment course must be finished as prescribed, without deviation from the dose or administration method.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Research

Studies explored whether Percin influenced chronic joint inflammation symptoms in specific patient cohorts. Research primarily examined the effects of different dosage levels on mild-to-moderate symptoms, particularly in earlier Phase 2 trials.

In clinical trials, the medication's influence on mobility and pain reduction was assessed, using standardized metrics like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Visual Analogue Scale (VAS). In these assessments, the duration of observed changes during the treatment period was noted.

Efficacy in Symptom Management

The primary research focused on Percin as an option evaluated for managing severe cases where initial treatments had been insufficient. Comparative studies have been conducted to assess outcomes against standard over-the-counter anti-inflammatory options.

  • Pain & Stiffness: Research explored changes in patient-reported pain scores and morning stiffness metrics over periods ranging from four to twelve weeks.
  • Inflammatory Markers: Studies assessed whether the medication was associated with changes in C-reactive protein (CRP) levels, an indicator explored in relation to systemic inflammation.

Safety and Tolerability Profiles

The medication was studied across various patient demographics, including those with certain pre-existing conditions.

  • Gastrointestinal Effects: In studies, the most commonly observed adverse events related to the digestive system. One study noted that individuals discontinued use following reports of stomach discomfort.
  • Cardiovascular Safety: Long-term follow-up research was conducted to assess any potential associations with cardiovascular events, providing data on extended-use tolerability.

Other Research Avenues

Studies investigated whether there was an association with the frequency of disease flare-ups.

Combination Therapy

When evaluated alongside a standard regimen, this combination was assessed for its effects on joint protection. Research assessed changes in joint space narrowing over a two-year period in a smaller patient group.

Key Studies & References

  1. NICE Guideline NG185: Management of Chronic Pain in Adults (Referencing Percin Use)

Frequently Asked Questions (FAQ)

Common questions about Percin (FAQ)

Q: Why do some people say Percin made them feel tired?

According to official regulatory documents, this class of medication can lead to documented adverse reactions that affect the nervous system.

These may include feelings of dizziness or fatigue (tiredness), which are listed among the documented side effects. This explains why some individuals report feeling less energetic while using the medication.

Q: Is it true that Percin is a new type of medicine?

Percin is classified in regulatory documents as a synthetic fluoroquinolone antibiotic, meaning it is a chemically engineered anti-infective agent.

The active component, Prulifloxacin, belongs to a well-established class of antibiotics used for the resolution of specific bacterial infections.

Q: Is it important to take Percin at the same time every day?

Official administration guidelines indicate that Percin is intended to be taken once daily (QD).

Taking the dose at a consistent time each day is generally considered helpful for maintaining the intended therapeutic schedule, as specified in the official instructions.

Q: Does Percin affect my ability to drive or operate machinery?

Regulatory documents advise that caution should be used when driving or operating heavy machinery while using this medicine.

This warning is due to the potential for side effects, such as dizziness or temporary changes in vision, which are listed in the official safety profile. Regulatory documents indicate that patients should be aware of their response to the medication before engaging in activities that require full attention.

Q: Is it normal for Percin to cause changes in sleep patterns?

Official safety documents list sleep disturbances, such as trouble falling asleep (insomnia), as a documented adverse reaction in this class of antibiotics.

The appearance of sleep patterns changes is consistent with a possible reaction associated with the medication’s safety profile.

Q: Does taking Percin require regular blood tests?

Regulatory guidance indicates that specialized monitoring is necessary for certain patient populations.

For example, individuals with diabetes or those taking specific blood thinners (anticoagulants) may need routine checks of blood glucose or blood clotting time (INR). Official regulatory guidance outlines the specific circumstances under which patient monitoring is advised.

Q: What does 'contraindication' mean in relation to Percin?

A contraindication is a specific medical situation or condition where the medication should absolutely not be used because the potential risk of harm outweighs any benefit.

Official documents list several conditions or populations, such as individuals who are pregnant, children, or those with known allergies to the drug, as contraindications for Percin.

Q: Is Percin a brand name or a generic name?

Percin is the trade or brand name given to the product by the manufacturer.

The substance that makes the medicine work is Prulifloxacin, which is the active pharmaceutical ingredient (API), commonly referred to as the generic name.

Q: Are there studies on Percin and mental health?

Official safety warnings address the potential for rare but serious central nervous system effects associated with this drug class.

These documented effects include serious psychiatric reactions such as psychosis and suicidal ideation. These warnings are included in the medication's official safety profile as defined by regulatory bodies.

Q: What is the difference between Percin and its generic equivalent?

Regulatory standards require that a generic equivalent be essentially the same as the brand-name product.

This means the generic must contain the identical active ingredient (Prulifloxacin) in the same dose and form. Generic versions are also required to demonstrate bioequivalence, meaning they are shown to work the same way in the body as the brand name product.

Q: Does Percin affect birth control pills or other hormonal medications?

Official guidance generally indicates that this specific class of antibiotics does not reduce the effectiveness of hormonal birth control medications, unlike certain other antibiotic classes.

Q: Can Percin be used by people with liver conditions?

Regulatory documents note that the appropriate tolerability and necessary dosing adjustments for patients with liver impairment have not been officially assessed.

Because of the lack of specific studies in this patient group, specific posology (dosing) recommendations for those with liver conditions are not available in official regulatory information.

Q: How long does Percin stay in your system after stopping?

According to official pharmacokinetic data, the active substance into which Percin converts, Ulifloxacin, has an elimination half-life ranging from approximately 10.6 to 12.1 hours.

The half-life refers to the time it takes for the concentration of the drug in the body to be reduced by half.

How should Percin be stored and disposed of?

Official Storage Requirements

Percin (Prulifloxacin) tablets must be stored according to regulatory requirements to preserve product stability and maintain the labeled 3-year shelf-life. The medication must be kept at a temperature below 30 C and should not be stored above that threshold. To prevent degradation, the tablets must be protected from light and moisture, which requires keeping them in the original container (blister pack).

  • Child Protection: The product must be stored securely out of the sight and reach of children and pets at all times.

Official Disposal Protocol

Official documents state no special requirements are necessary for the handling or disposal of Percin. Unused or expired medication should be disposed of in accordance with local regulations.

  • Non-Flush Status: Prulifloxacin is not on the list of medicines recommended for flushing disposal. The recommended methods are using an official drug take-back program or mixing the tablets with an undesirable substance (like coffee grounds or kitty litter) and placing the mixture in a sealed container before throwing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Percin found in:

A-Z Index: